These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 38170548)

  • 21. First-line PARP inhibitors in ovarian cancer: summary of an
    Banerjee S; Gonzalez-Martin A; Harter P; Lorusso D; Moore KN; Oaknin A; Ray-Coquard I
    ESMO Open; 2020 Nov; 5(6):e001110. PubMed ID: 33310779
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Olaparib: A Review as First-Line Maintenance Therapy in Advanced Ovarian Cancer.
    Paik J
    Target Oncol; 2021 Nov; 16(6):847-856. PubMed ID: 34623572
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of niraparib, rucaparib, and olaparib for treatment of platinum-resistant, recurrent ovarian carcinoma.
    Wolford JE; Bai J; Moore KN; Kristeleit R; Monk BJ; Tewari KS
    Gynecol Oncol; 2020 May; 157(2):500-507. PubMed ID: 32173049
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Budget impact of niraparib as maintenance treatment in recurrent ovarian cancer following platinum-based chemotherapy.
    Neeser K; O'Neil WM; Stern L; Harrow B; Travers K
    J Comp Eff Res; 2019 Jun; 8(8):577-587. PubMed ID: 30935213
    [No Abstract]   [Full Text] [Related]  

  • 25. Cost-Effectiveness of Niraparib and Olaparib as Maintenance Therapy for Patients with Platinum-Sensitive Recurrent Ovarian Cancer.
    Zhong L; Tran AT; Tomasino T; Nugent E; Smith JA
    J Manag Care Spec Pharm; 2018 Dec; 24(12):1219-1228. PubMed ID: 30479195
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance.
    Wang L; Wang Q; Xu Y; Cui M; Han L
    Curr Drug Targets; 2020; 21(2):167-178. PubMed ID: 31553293
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Maintenance therapy for newly diagnosed epithelial ovarian cancer- a review.
    Nag S; Aggarwal S; Rauthan A; Warrier N
    J Ovarian Res; 2022 Jul; 15(1):88. PubMed ID: 35902911
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Real-world clinical data analysis of PARPi as first-line maintenance therapy in newly diagnosed epithelial ovarian cancer patients].
    Wang DF; Zhang J; Zhang C; Yu J; Shi Y; Xu SQ; Fan Y; Zhou FZ; Song SQ; Liu H; Zhang GN
    Zhonghua Fu Chan Ke Za Zhi; 2022 Sep; 57(9):641-652. PubMed ID: 36177575
    [No Abstract]   [Full Text] [Related]  

  • 29. PARP Inhibitors and the Evolving Landscape of Ovarian Cancer Management: A Review.
    Cook SA; Tinker AV
    BioDrugs; 2019 Jun; 33(3):255-273. PubMed ID: 30895466
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FDA Approval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian Cancer.
    Arora S; Balasubramaniam S; Zhang H; Berman T; Narayan P; Suzman D; Bloomquist E; Tang S; Gong Y; Sridhara R; Turcu FR; Chatterjee D; Saritas-Yildirim B; Ghosh S; Philip R; Pathak A; Gao JJ; Amiri-Kordestani L; Pazdur R; Beaver JA
    Oncologist; 2021 Jan; 26(1):e164-e172. PubMed ID: 33017510
    [TBL] [Abstract][Full Text] [Related]  

  • 31. U.S. Food and Drug Administration-Approved Poly (ADP-Ribose) Polymerase Inhibitor Maintenance Therapy for Recurrent Ovarian Cancer: A Cost-Effectiveness Analysis.
    Dottino JA; Moss HA; Lu KH; Secord AA; Havrilesky LJ
    Obstet Gynecol; 2019 Apr; 133(4):795-802. PubMed ID: 30870286
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of poly-(ADP-ribose) polymerase (PARP)-inhibitors for the maintenance treatment after responding to first- and second-line chemotherapy in advanced ovarian cancer.
    Giuliani J; Mantoan B; Ferrario L; Candela MV; Aprile G
    J Oncol Pharm Pract; 2023 Mar; 29(2):457-464. PubMed ID: 36344039
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An update on current and emerging therapies for epithelial ovarian cancer: Focus on poly(adenosine diphosphate-ribose) polymerase inhibition and antiangiogenesis.
    Chung C; Lee R
    J Oncol Pharm Pract; 2017 Sep; 23(6):454-469. PubMed ID: 27357817
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review.
    Lau CH; Seow KM; Chen KH
    Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897700
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The forefront of ovarian cancer therapy: update on PARP inhibitors.
    Mirza MR; Coleman RL; González-Martín A; Moore KN; Colombo N; Ray-Coquard I; Pignata S
    Ann Oncol; 2020 Sep; 31(9):1148-1159. PubMed ID: 32569725
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recent Insights into PARP and Immuno-Checkpoint Inhibitors in Epithelial Ovarian Cancer.
    Revythis A; Limbu A; Mikropoulos C; Ghose A; Sanchez E; Sheriff M; Boussios S
    Int J Environ Res Public Health; 2022 Jul; 19(14):. PubMed ID: 35886427
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of niraparib for the treatment of ovarian cancer.
    Ethier JL; Lheureux S; Oza AM
    Future Oncol; 2018 Oct; 14(25):2565-2577. PubMed ID: 29856239
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors as maintenance therapy in women with newly diagnosed ovarian cancer: a systematic review and meta-analysis.
    Cheng H; Yang J; Liu H; Xiang Y
    Arch Gynecol Obstet; 2021 Aug; 304(2):285-296. PubMed ID: 34021367
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of recurrent ovarian cancer.
    Pignata S; C Cecere S; Du Bois A; Harter P; Heitz F
    Ann Oncol; 2017 Nov; 28(suppl_8):viii51-viii56. PubMed ID: 29232464
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PARP inhibitors: risk factors for toxicity and matching patients to the proper poly (ADP-ribose) polymerase inhibitor (PARPi) therapy.
    Chelariu-Raicu A; Trillsch F; Burges A; Czogalla B; Hester A; Wuerstlein R; Harbeck N; Mahner S
    Int J Gynecol Cancer; 2023 May; 33(5):812-822. PubMed ID: 36707086
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.